Restrictive Coverage Policies and Patient Access

Please read this timely article by Mark Ballow, M.D. published in Healthcare Payer News. Dr. Ballow addresses restrictive coverage policies that have a negative impact on patient access and patient care; particularly focusing on patients with primary immunodeficiency diseases.

PPTA News

Final Summary of the PPTA/FDA Liaison Meeting on September 14, 2022 +

The following is a final summary of the PPTA-FDA Liaison Meeting held virtually on September 14, 2022.

Welcome, Introductions & Meeting Guidelines

PPTA and Head of Global Plasma welcomed all participants and appreciated FDA’s participation in today’s meeting. PPTA’s Head of Global Regulatory Policy opened the meeting with introductory remarks. PPTA’s External Legal Counsel advised the participants on the meeting guidelines and the antitrust statement.
Read More
International Plasma Awareness Week 2022: Donate Locally. Think Globally. +

ANNAPOLIS, MD (October 3, 2022) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the 10th annual International Plasma Awareness Week (IPAW), which will run from Monday, October 3 until Friday, October 7. Hundreds of thousands of people in the U.S. who live with these rare diseases, and countless others facing trauma and emergency medical needs every day, rely on plasma-derived therapies that are only available because of the commitment of dedicated plasma donors.
Read More
HHS Launches Plasma and Blood Donation Campaign +

On August 4, the U.S. Department of Health and Human Services (HHS) launched a new nationwide campaign, Giving=Living, intended to draw awareness to the importance of plasma and blood donation, especially following a steep decline in both caused by the Covid pandemic.
Read More
PPTA Statement on the draft EU Substances of Human Origin Regulation +

PPTA welcomes positive developments but regrets missed opportunities to support plasma donors and patients who rely on plasma-derived medicinal products (PDMPs)

Brussels, Belgium (July 14, 2022). While the text of the draft regulation on Substances of Human Origin (SoHo) addresses a number of PPTA’s concerns, it has missed the opportunity to help Member States increase plasma collection to improve the reliable availability of life-saving, plasma-derived therapies to patients with a wide range of rare and complex, chronic diseases. As much as 38% of the plasma used to produce medicines for the EU’s 300,000 rare disease patients who rely on PDMPs comes from the U.S., a reliance highlighted during the pandemic, when critical plasma donations declined significantly.
Read More

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published three times a year.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives.
Find a Donation Center.

The need for plasma and plasma donors is more urgent than ever before. Visit givingplasma.org to learn more and to find a donation center near you.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Restrictive Coverage Policies and Patient Access

Final Summary of the PPTA/FDA Liaison Meeting on September 14, 2022 +

International Plasma Awareness Week 2022: Donate Locally. Think Globally. +

HHS Launches Plasma and Blood Donation Campaign +

PPTA Statement on the draft EU Substances of Human Origin Regulation +

Media and Information

Advocacy